The Treasury Department is urging money transfer companies to increase their oversight of international transfers, while the ...
Jen Shah is officially out of prison. The Real Housewives of Salt Lake City alum, 52, was released on Wednesday, December 10, ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin” or the 'Company”), a late-stage pharmaceutical company with a broad ...
Soligenix Inc. today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized ...
TuHURA Biosciences, Inc. ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has ...
Are y'all ready to go Beyond the Gates? Derek finally told Ashley what time it was, while Smitty went up against Joey and ...
Detailed price information for Cellebrite Di Ltd (CLBT-Q) from The Globe and Mail including charting and trades.
The Kenya Times on MSNOpinion
Investor beware: Concerns over Nairobi Securities Exchange deal with Somalia
Somalia is witnessing a financial awakening. For the first time in decades, the conversation in Mogadishu has shifted from ...
7don MSN
Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...
Among a heavily pretreated, older adult population of patients with relapsed/refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML), revumenib was associated with a clinically ...
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in ...
News-Medical.Net on MSN
Aza-ven shows superior outcomes compared to induction chemotherapy in AML patients
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results